All In Biotech

Drug Trial Radar · NCT06544499

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

69

Planned (sponsor's estimate)

Start

Oct 18, 2024

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • Efgartigimod IVBiological

    Intravenous infusion of efgartigimod

  • Placebo IVOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extent of disease control, defined as the number of cumulative weeks during the 24-week Double-Blinded Treatment Period with platelet counts of at least 50 × 10^9/LTime frame: Up to 24 weeks

Locations

94 sites in 17 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital Scottsdale

    Phoenix, Arizona · Recruiting

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Sharp Memorial Hospital

    Oceanside, California · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • The University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • The University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • Tulane University

    New Orleans, Louisiana · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Regional Cancer Care Associates, LLC (RCCA)

    Little Silver, New Jersey · Recruiting

  • Clinical Research Alliance Inc.

    Westbury, New York · Terminated

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Ohio State University Hospital East

    Columbus, Ohio · Recruiting

  • INTEGRIS Cancer Institute of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • Allgemeines Krankenhaus der Stadt Linz

    Linz, Austria · Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria · Recruiting

  • Klinikum Kreuzschwestern Wels

    Wels, Austria · Recruiting

  • Acibadem City clinic Tokuda hospital

    Sofia, Bulgaria · Recruiting

  • UMHAT Aleksandrovska

    Sofia, Bulgaria · Recruiting

  • University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski

    Sofia, Bulgaria · Recruiting

  • National Specialized Hospital for Active Treatment of Hematology Diseases

    Sofia, Bulgaria · Recruiting

  • UMHAT SofiaMed

    Sofia, Bulgaria · Recruiting

  • University Hospital Prof. Dr. Stoyan Kirkovich AD

    Stara Zagora, Bulgaria · Recruiting

  • Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital Of Bengbu Medical College

    Bengbu, China · Recruiting

  • The Affiliated Hospital of Chengde Medical University

    Chengde, China · Recruiting

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, China · Recruiting

  • The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

    Huai'an, China · Recruiting

  • Huizhou Central People's Hospital

    Huizhou, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, China · Recruiting

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)

    Wuhan, China · Recruiting

  • Wuxi People's Hospital (Wuxi No.1 People's Hospital)

    Wuxi, China · Recruiting

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, China · Recruiting

  • University Hospital Center Zagreb

    Zagreb, Croatia · Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia · Recruiting

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.